Placebo News and Research

RSS

Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal gastrointestinal (GI) mucosal findings on capsule endoscopy.

8 Nov 2021

International Alzheimer’s trial to evaluate a combination of drugs targeting two brain proteins

Trial participant Rachel Habiger meets in 2018 with Randall J. Bateman, MD, the director of the Dominantly Inherited Alzheimer Network Trials Unit at Washington University School of Medicine in St. Louis.

8 Nov 2021

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

A new study describes a new small molecule compound that has shown impressive safety, tolerability, and bioavailability against SARS-CoV-2.

7 Nov 2021

Diabetes medication reduces the rate of kidney function decline in CKD patients

Clinical trial data reveal that dapagliflozin - a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes - reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Arginine treatment enhances effectiveness of radiation therapy in cancer patients with brain metastases

Treatment with arginine, one of the amino-acid building blocks of proteins, enhanced the effectiveness of radiation therapy in cancer patients with brain metastases, in a proof-of-concept, randomized clinical trial from investigators at Weill Cornell Medicine and Angel H. Roffo Cancer Institute.

7 Nov 2021

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba.

4 Nov 2021

Novel drug improves management of ulcerative colitis

A new drug improved management of ulcerative colitis, according to a study published in the New England Journal of Medicine.

2 Nov 2021

Zinc supplement may help prevent symptoms of respiratory tract infections, analysis finds

A zinc supplement might help stave off the symptoms of respiratory tract infections, such as coughing, congestion, and sore throat, and cut illness duration, suggests a pooled analysis of the available evidence, published in the open access journal BMJ Open.

2 Nov 2021

What do we really know about vaccine effectiveness?

The politicization of covid vaccines — and, well, just about everything else having to do with the pandemic — has led to confusion, if not utter fatigue.

2 Nov 2021

Stanford neuromodulation therapy causes remission in almost 80% of patients with severe depression

A new type of magnetic brain stimulation brought rapid remission to almost 80% of participants with severe depression in a study conducted at the Stanford University School of Medicine.

30 Oct 2021

Magnus Medical receives FDA's Breakthrough Device Designation for rapid-acting technology to treat major depression

Magnus Medical, Inc., a medical device company, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments.

29 Oct 2021

Study finds early fluvoxamine treatment among COVID-19 patients reduces hospitalization

A team of researchers conducted a randomized, placebo-controlled, adaptive platform trial to evaluate the efficacy of fluvoxamine to prevent COVID-19 progression and hospitalization.

29 Oct 2021

Importance of boosters after priming with J&J Ad26.COV2.S COVID-19 vaccine

A new study compares healthcare workers who underwent homologous Ad26.COV2.S booster vaccination to those who underwent heterologous boosting.

28 Oct 2021

Study offers hope for a new therapeutic option for patients with severe asthma

A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Medicine.

28 Oct 2021

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

The results of a new randomized clinical trial, published in The Lancet Global Health, have demonstrated that using fluvoxamine to treat high-risk outpatients with early-diagnosed COVID-19 reduced the need for prolonged observation in an emergency setting or hospitalization, compared to a control group who received a placebo.

28 Oct 2021

A low-cost repurposed drug can save COVID-19 patients' lives

An inexpensive repurposed drug called fluvoxamine can save the lives of COVID-19 patients and cut hospital admissions by up to 30 per cent, says a study co-led by McMaster University.

27 Oct 2021

Cholesterol-lowering drugs not helpful in reducing COVID-related mortality or severity

In the worldwide effort to battle SARS-CoV-2, the virus that causes COVID-19, researchers have often turned to medications used as therapies for other conditions in the hopes of finding ones that either kill the coronavirus or lessen the impacts from its infection.

26 Oct 2021

Antidepressant offers no improvement in agitation for people with dementia, study shows

A drug used to treat agitation in people with dementia is no more effective than a placebo, and might even increase mortality, according to a new study.

22 Oct 2021

Researchers employ novel algorithm to identify candidate cancer drugs for pulmonary hypertension

By combining computational and experimental approaches, University of Pittsburgh School of Medicine and Prairie View A&M University researchers identified cancer drugs that show promise for treating pulmonary hypertension, or PH, a rare and incurable lung disease.

21 Oct 2021

Placebo News and Research

Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

International Alzheimer’s trial to evaluate a combination of drugs targeting two brain proteins

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Diabetes medication reduces the rate of kidney function decline in CKD patients

Arginine treatment enhances effectiveness of radiation therapy in cancer patients with brain metastases

Results of high-impact clinical trials could affect kidney-related medical care

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

Novel drug improves management of ulcerative colitis

Zinc supplement may help prevent symptoms of respiratory tract infections, analysis finds

What do we really know about vaccine effectiveness?

Stanford neuromodulation therapy causes remission in almost 80% of patients with severe depression

Magnus Medical receives FDA's Breakthrough Device Designation for rapid-acting technology to treat major depression

Study finds early fluvoxamine treatment among COVID-19 patients reduces hospitalization

Importance of boosters after priming with J&J Ad26.COV2.S COVID-19 vaccine

Study offers hope for a new therapeutic option for patients with severe asthma

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

A low-cost repurposed drug can save COVID-19 patients' lives

Cholesterol-lowering drugs not helpful in reducing COVID-related mortality or severity

Antidepressant offers no improvement in agitation for people with dementia, study shows

Researchers employ novel algorithm to identify candidate cancer drugs for pulmonary hypertension

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News